Latest Breaking News On - Angelos stergiou - Page 5 : comparemela.com

SELLAS Life Sciences (SLS) Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo

SELLAS Life Sciences (SLS) Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Angelos stergiouNational cancer instituteSellas life sciences group incSciences groupWilms tumor

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed

-Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed -

United statesBruce mackleAngelos stergiouLife sciences group incNational cancer instituteGenfleet therapeutics shanghai incMemorial sloan kettering cancer centerBristol myers squibbLifesci advisorsPrimary endpointEfficacy metClinical activityIncreased survival observedMedian overall survivalPatients treatedCombination therapy

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesBruce mackleAngelos stergiouNational cancer instituteLife sciences reports positiveLife sciences group incMemorial sloan kettering cancer centerBristol myers squibbGenfleet therapeutics shanghai incLifesci advisorsSurvival dataCompleted phaseGalinpepimuts combinedAdvanced malignant pleuralEfficacy metClinical activity

SELLAS receives orphan drug designation for PTCL therapy

SELLAS has received ODD from the US FDA for SLS009, a new CDK9 inhibitor aimed at treating relapsed/refractory Peripheral T-cell Lymphomas (PTCL).

Angelos stergiouGenfleet therapeutics

SELLAS Life Sciences (SLS) Granted FDA Orphan Drug Designation for SLS009

SELLAS Life Sciences (SLS) Granted FDA Orphan Drug Designation for SLS009
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAngelos stergiouDrug administrationOffice of orphan products developmentGenfleet therapeutics incSellas life sciences group incSciences groupOrphan drug designationPeripheralt cell lymphomasFast track designationChief executive officerGenfleet therapeuticsOrphan products development